Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Taian City Central Hospital | OTHER |
| Dezhou People's Hospital | OTHER |
| Weifang Medical University | OTHER |
| The Affiliated Hospital of Qingdao University |
Not provided
Not provided
Not provided
Not provided
The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.
Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer.
At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment in patients with Hp eradication failure.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Amoxicillin-Levofloxacin-Esomeprazole-containing quadruple group | Patients in amoxicillin-levofloxacin-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d. |
| |
| Amoxicillin-Furazolidone-Esomeprazole-containing quadruple group | Patients in amoxicillin-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d. |
| |
| Tetracycline-Furazolidone-Esomeprazole-containing quadruple group | Patients in tetracycline-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d. |
| |
| Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group | Patients in amoxicillin-levofloxacin-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amoxicillin , Levofloxacin and Esomeprazole | Drug | Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens |
|
| Measure | Description | Time Frame |
|---|---|---|
| The most suitable re-eradication time | The most suitable re-eradication time will be assessed by paired comparison method . | 1year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The patients in Shandong province,aged between 18 and 70 years old, with positive H. pylori infection that was eradicated by previous therapies but failed are included.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Xiuli Zuo, MD,PhD | Qilu Hospital of Shandong University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qilu Hospital of Shandong University | Jinan | Shandong | 257000 | China |
Not provided
| OTHER |
| Shengli Oilfield Hospital | OTHER |
Not provided
Not provided
Not provided
| Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group | Patients in amoxicillin-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d. |
|
| Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group | Patients in tetracycline-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d. |
|
| Amoxicillin , Furazolidone and Esomeprazole | Drug | Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens |
|
| Tetracycline , Furazolidone and Esomeprazole | Drug | Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens |
|
| Amoxicillin,Levofloxacin and Vonoprazan fumarate | Drug | Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group |
|
| Amoxicillin,Furazolidone and Vonoprazan fumarate | Drug | Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group |
|
| Tetracycline,Furazolidone and Vonoprazan fumarate | Drug | Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group |
|
| ID | Term |
|---|---|
| D000658 | Amoxicillin |
| D064704 | Levofloxacin |
| D064098 | Esomeprazole |
| D005664 | Furazolidone |
| D013752 | Tetracycline |
| ID | Term |
|---|---|
| D000667 | Ampicillin |
| D010400 | Penicillin G |
| D010406 | Penicillins |
| D047090 | beta-Lactams |
| D007769 | Lactams |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D015242 | Ofloxacin |
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
| D009853 | Omeprazole |
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D001562 | Benzimidazoles |
| D009581 | Nitrofurans |
| D009574 | Nitro Compounds |
| D023303 | Oxazolidinones |
| D010080 | Oxazoles |
| D001393 | Azoles |
| D005663 | Furans |
| D013754 | Tetracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011083 | Polycyclic Compounds |
Not provided
Not provided